Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 50.3% during the second quarter, HoldingsChannel reports. The firm owned 163,007 shares of the biopharmaceutical company’s stock after purchasing an additional 54,517 shares during the quarter. Squarepoint Ops LLC’s holdings in Celldex Therapeutics were worth $6,033,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. lifted its stake in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after purchasing an additional 654,194 shares during the period. Marshall Wace LLP lifted its stake in shares of Celldex Therapeutics by 53.3% during the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after purchasing an additional 479,068 shares during the period. Magnetar Financial LLC lifted its stake in shares of Celldex Therapeutics by 61.4% during the 2nd quarter. Magnetar Financial LLC now owns 17,390 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 6,613 shares during the period. HighVista Strategies LLC purchased a new position in shares of Celldex Therapeutics during the 2nd quarter worth $356,000. Finally, American Century Companies Inc. raised its position in shares of Celldex Therapeutics by 128.5% in the 2nd quarter. American Century Companies Inc. now owns 416,000 shares of the biopharmaceutical company’s stock worth $15,396,000 after buying an additional 233,928 shares during the period.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $33.20 on Monday. The business’s 50-day moving average is $38.35 and its two-hundred day moving average is $38.29. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18. The firm has a market capitalization of $2.19 billion, a PE ratio of -11.65 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.

Analysts Set New Price Targets

CLDX has been the topic of several research reports. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday. Finally, Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $63.83.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.